FDA clears oral semaglutide pill

A daily semaglutide pill is now an approved United States weight-loss drug, giving patients a needle-free version of Wegovy. (accessdata.fda.gov) The Food and Drug Administration cleared Wegovy tablets in December 2025 for adults with obesity, or adults who are overweight and have at least one weight-related condition, alongside diet and physical activity. The label lists oral use at 25 milligrams once daily and carries the same boxed warning about thyroid C-cell tumors seen with semaglutide products. (accessdata.fda.gov) Semaglutide is a glucagon-like peptide-1 drug, a class that mimics a gut hormone that helps people feel fuller and eat less. Until this approval, Wegovy for weight loss was best known as a once-weekly injection, while the oral form of semaglutide had been used under other brand names for diabetes. (dailymed.nlm.nih.gov) The approval rested in part on the phase 3 OASIS 4 trial, which tested once-daily oral semaglutide 25 milligrams in 307 adults without diabetes over 64 weeks. In the treatment-policy analysis, average weight loss was 13.6% with the pill versus 2.2% with placebo; in an analysis assuming full adherence, average loss was 16.6% versus 2.7%. (nejm.org) More than a third of adherent participants taking oral semaglutide, 34.4%, lost at least 20% of body weight, compared with 2.9% on placebo. Serious adverse events were reported less often with oral semaglutide than placebo, 3.9% versus 8.8%, while stomach-related side effects remained common. (nejm.org) The pill arrives as drugmakers push to widen access beyond injections that require pens, refrigeration routines, or training. Eli Lilly’s oral obesity drug, orforglipron, won Food and Drug Administration approval in April 2026, setting up a direct pill-versus-pill competition in the same market. (managedhealthcareexecutive.com) A separate line of research points to why patients on these drugs do not all get the same result. A Nature study published online on April 8, 2026 analyzed self-reported outcomes from 27,885 people and found that a variant in the GLP1R gene was linked to an extra 0.76 kilograms of weight loss per copy of the effect allele. (nature.com) The same study linked other genetic variants to side effects including nausea, vomiting, diarrhea, constipation and acid reflux symptoms. The authors said the findings help explain part of the wide patient-to-patient variation seen with glucagon-like peptide-1 therapies, including semaglutide and tirzepatide. (nature.com) That genetics work does not change prescribing on its own. It adds a second reality to the new pill era: the drug is now easier to take for many patients, but how much weight a person loses — and what side effects they get — may still differ in ways doctors cannot yet fully predict. (nature.com; accessdata.fda.gov)